A Double-Blind, Randomised, Parallel-Group, Placebo-Controlled, MultiCentre, Phase IIa Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Multiple Oral Doses of AZD3480 in Schizophrenic Patients on Stable Antipsychotic Monotherapy with quetiapine, risperidone or olanzapine.
Phase of Trial: Phase II
Latest Information Update: 06 Aug 2013
At a glance
- Drugs Ispronicline (Primary) ; Olanzapine; Quetiapine; Risperidone
- Indications Schizophrenia
- Focus Adverse reactions
- 06 Aug 2013 Status changed from recruiting to completed.
- 07 Jul 2011 New trial record